Ventyx Biosciences
A biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets.
Launch date
Employees
Market cap
CAD207m
Enterprise valuation
(CAD104m) (Public information from Sep 2024)
Share price
$2.29 VTYX
Encinitas California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | - | 66.7m |
| EBITDA | (7.1m) | (72.6m) | (108m) | (207m) | (155m) | (157m) | (187m) |
| % EBITDA margin | - | - | - | - | - | - | (281 %) |
| Profit | (28.2m) | (83.7m) | (108m) | (193m) | (148m) | (178m) | (151m) |
| % profit margin | - | - | - | - | - | - | (227 %) |
| EV / revenue | - | - | - | - | - | - | 2.4x |
| EV / EBITDA | - | -13.8x | -14.2x | 0.8x | 0.6x | 1.5x | -0.8x |
| R&D budget | 6.4m | 58.5m | 87.7m | 176m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$114m | Early VC | ||
$51.0m Valuation: $570m -80.8x EV/LTM EBITDA | Series B | ||
| N/A | $152m | IPO | |
* | $177m | Post IPO Equity | |
* | $100m | Private Placement VC | |
| Total Funding | CAD361m | ||
Related Content
Recent News about Ventyx Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.